NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders

CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de

AccesswireMar 1 09:00 ET

NovAccess Global Jumps on Announcing $10.7 Million Financing

Seeking AlphaJan 2 10:54 ET

NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit

Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit.Event:December 7th In

newsfileDec 1, 2023 16:51 ET

NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board

CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app

AccesswireNov 10, 2023 09:00 ET

NovAccess Global Partners With BCN Biosciences to Expand Immunotherapy Platform

Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS TumorsPotential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology MarketCLEVELAND, OH /

AccesswireJul 27, 2023 08:30 ET

NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day

CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv

AccesswireJul 13, 2023 08:30 ET